IGF-IEc expression is associated with advanced clinical and pathological stage of prostate cancer

Anticancer Res. 2013 Jun;33(6):2441-5.


Background: Recent evidence suggests a role for the insulin-like growth factor-1Ec (IGF-IEc) transcript variant in cancer biology. The aim of the present study was to investigate whether IGF-IEc expression is associated with prostate cancer stage.

Materials and methods: Formalin-fixed and paraffin-embedded prostate cancer surgical specimens from 83 patients were assessed by immunohistochemistry for IGF-IEc expression.

Results: Normal prostate epithelium was negative or demonstrated mild IGF-IEc cytoplasmic expression whereas prostate cancer exhibited mild to strong cytoplasmic immunoexpression. The mean IGF-1Ec expression, was significantly lower (p=0.004) in localized (stage ≤ IIb) prostate cancer, compared to locally advanced tumors (stage ≥ III). Only one out of 83 (1.2%) prostate cancer samples was completely negative for IGF-IEc. A weak-positive correlation was also observed between IGF-IEc expression levels and Gleason score (r=0.247; p=0.024).

Conclusion: The present data demonstrate that the expression of IGF-IEc is positively-associated with more advanced stage and higher Gleason score of prostate carcinomas.

Keywords: IGF1Ec; Prostate cancer; immunohistochemistry; insulin-like growth factor 1 (IGF-1); mechano-growth factor (MGF).

MeSH terms

  • Aged
  • Humans
  • Immunohistochemistry
  • Insulin-Like Growth Factor I / metabolism*
  • Male
  • Neoplasm Grading
  • Neoplasm Staging
  • Paraffin Embedding
  • Prognosis
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology*
  • Receptor, IGF Type 1 / metabolism*
  • Tissue Fixation


  • Insulin-Like Growth Factor I
  • Receptor, IGF Type 1